ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

First, select a broad health condition.
31648 results sorted by trial registration date.
Clear all

  • Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

    This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.

    Registration number:
    NCT04655118
    Broad health category:
    • Myelofibrosis
    • Indolent Systemic Mastocytosis
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

    The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).

    Registration number:
    NCT04650581
    Broad health category:
    • Breast Cancer
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Active, not recruiting
    Recruitment sites:
    • NSW
    • QLD
    • VIC
    • WA
    • Not specified
    Gender:
    • All

  • Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

    Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

    Registration number:
    NCT04650542
    Broad health category:
    • Drug-drug Interaction
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • VIC
    • Not specified
    Gender:
    • All

  • Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

    This is a double-blind, parallel group and placebo-controlled clinical study to assess safety tolerability, pharmacokinetics and pharmacodynamics of Atrosimab in healthy volunteers

    Registration number:
    NCT04650126
    Broad health category:
    • Healthy Volunteers
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

    The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.

    Registration number:
    NCT04649385
    Broad health category:
    • Advanced Solid Tumor
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Active, not recruiting
    Recruitment sites:
    • NSW
    • SA
    • VIC
    • WA
    • Not specified
    Gender:
    • All

  • MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

    The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

    Registration number:
    NCT04649359
    Broad health category:
    • Multiple Myeloma
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Active, not recruiting
    Recruitment sites:
    • VIC
    • Not specified
    Gender:
    • All

  • Advanced Techniques For Single-fraction Palliative Radiotherapy Versus Standard Multi Fraction Radiation

    The aim of the study is to determine if single fraction dose escalated palliative radiotherapy results in a prolonged duration of benefit for patients otherwise suitable for Multifraction (5-10#) palliative radiation. The primary endpointis to determine the percentage of patients who have achieved a substantial benefit from palliative radiotherapy and have not redeveloped symptoms by 12 months post treatment

    Registration number:
    NCT04649125
    Broad health category:
    • Palliative Radiotherapy
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • NSW
    • Not specified
    Gender:
    • All

  • Effects of FT011 in Systemic Sclerosis

    FT011 is an anti-fibrotic drug that is being tested as a treatment for scleroderma. This study is being conducted to see what the body does to the drug (pharmacokinetics), and what the drug does to the body (pharmacodynamics).

    Registration number:
    NCT04647890
    Broad health category:
    • Scleroderma, Systemic
    • Scleroderma, Diffuse
    • Sclerosis, Systemic
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • SA
    • VIC
    • Not specified
    Gender:
    • All

  • ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

    ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .

    Registration number:
    NCT04645069
    Broad health category:
    • Advanced/Metastatic Solid Tumors
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • NSW
    • QLD
    • VIC
    • WA
    • Not specified
    Gender:
    • All

  • Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

    Primary Objective: \- To evaluate the long-term safety of BIVV001 in previously treated subjects with hemophilia A Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes. * To evaluate BIVV001 consumption for prevention and treatment of bleeding episodes. * To evaluate the effect of BIVV001 prophylaxis on joint health outcomes. * To evaluate the effect of BIVV001 prophylaxis on Quality of Life (QoL) outcomes. * To evaluate the safety and tolerability of BIVV001 treatment. * To assess the PK of BIVV001 based on the one stage activated partial thromboplastin time (aPTT) and two-stage chromogenic FVIII activity assays (only applicable to Arm B). * To evaluate the efficacy of BIVV001 for perioperative management

    Registration number:
    NCT04644575
    Broad health category:
    • Hemophilia A
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Active, not recruiting
    Recruitment sites:
    • NSW
    • QLD
    • WA
    • Not specified
    Gender:
    • All
Tags:
  • Finding clinical trials